Antengene receives approval for ATG-016 clinical trial in myelodysplastic syndrome

Antengene, a leading Chinese biopharmaceutical company, has announced a significant milestone with the approval of its Phase 1/2 clinical trial for ATG-016 (eltanexor) in the ... Read More